Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received three drug license suspension orders from drug control authorities. One store in Karnataka (BSK BDA Complex) faced a 2-day suspension with an estimated revenue loss of about Rs 1.85 lakh. Two stores in Maharashtra (Piramal Nagar, Goregaon and Ganesh Bhuvan, Mulund in Mumbai) faced suspensions of 7 days and 5 days, with estimated revenue losses of Rs 2.59 lakh and Rs 2.45 lakh respectively. All orders were received on August 18, 2025, and were issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The total potential revenue impact across the three stores is approximately Rs 6.89 lakh.
The financial impact is negligible — under Rs 7 lakh in total — compared to Medplus's overall scale of operations across thousands of stores, so this is unlikely to move the stock. However, repeated license suspensions could attract regulatory scrutiny if they become a pattern.